论文部分内容阅读
目的:点评与分析儿童患者单唾液酸四己糖神经节苷脂钠(GM1)临床用药情况,为规范临床合理用药和加强医院辅助用药管理提供参考。方法:选取2016年7—9月间收治的临床采用GM1治疗的270例患儿的临床资料,分别对其适应证、给药剂量、疗程进行点评,分析其用药的合理性。结果:270例使用GM1治疗的病例中,其医嘱合格率为40.37%,不合格医嘱中无适应证用药或适应证不适宜的占构成比的92.55%。结论:临床药师通过辅助用药专项点评,对不合理用药提出相应措施,有效规范了医院GM1的临床使用。
OBJECTIVE: To review and analyze the clinical use of monosialotetrahexosyl ganglioside sodium (GM1) in children and to provide reference for standardizing the rational use of drugs and strengthening the administration of adjuvant drugs in hospitals. METHODS: The clinical data of 270 children clinically treated with GM1 admitted from July to September in 2016 were selected and their indications, dosage and course of treatment were reviewed respectively. The rationality of their medication was analyzed. Results: Among the 270 cases treated with GM1, the pass rate of medical orders was 40.37%. The proportion of unqualified medical orders or inappropriate indications was 92.55%. Conclusion: Clinical pharmacists through the special reviews of adjuvant drugs, put forward appropriate measures to irrational drug use, effectively regulate the clinical use of the hospital GM1.